NCT06311149 Multicenter Evaluation of Patients Using LATITUDE Monitoring System
| NCT ID | NCT06311149 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Ferrara |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2043-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2023-12-01 with a primary completion date of 2043-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Multitude is a registry of patients who receive commercially available CIEDs that remotely communicate through the LATITUDE monitoring system and transfer data to a central database. The registry is designed to constitute a shared environment for the collection, management, analysis and reporting of clinical and diagnostic data, adopted by a network of European scientifically-motivated physicians who use rhythm management diagnostic and therapeutic solutions from Boston Scientific in their clinical practice. The Multitude study will facilitate the sharing of scientific proposals within a large network of researchers, and it will allow researchers to record the experience with medical devices throughout the device and patient lifecycle.
Eligibility Criteria
Inclusion Criteria: * Subject is willing and capable of providing informed consent to collect/store/process personal health information by the sponsor or such consent is provided by a legally designated representative, if required by local law or regulation. * Subject is: 1. prospectively scheduled for receiving a device monitored through the LATITUDE monitoring system 2. retrospectively enrolled after having received a device monitored through the LATITUDE monitoring system Exclusion Criteria: * Subject foreseen not to be followed at the enrolling center for at least 1 year after having received the device. * Subject is receiving a device that is not approved for commercial use at the time of procedure.
Contact & Investigator
Matteo Bertini, Prof
PRINCIPAL INVESTIGATOR
Azienda Ospedaliera Universitaria di Ferrara
Frequently Asked Questions
Who can join the NCT06311149 clinical trial?
This trial is open to participants of all sexes, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06311149 currently recruiting?
Yes, NCT06311149 is actively recruiting participants. Contact the research team at doc.matber@gmail.com for enrollment information.
Where is the NCT06311149 trial being conducted?
This trial is being conducted at Ferrara, Italy, Naples, Italy, Roma, Italy.
Who is sponsoring the NCT06311149 clinical trial?
NCT06311149 is sponsored by University Hospital of Ferrara. The principal investigator is Matteo Bertini, Prof at Azienda Ospedaliera Universitaria di Ferrara. The trial plans to enroll 20,000 participants.